The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Children and adolescents with hypothalamic obesity have low sympathetic tone (142, 143), and thus may benefit from the stimulant-induced decrease in appetite (138, 144).”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [143]
In the citing paper
“Reports of other types of stimulant use in individuals with hypothalamic obesity such as amphetamines have generally demonstrated weight loss or attenuation of weight gain (121, 122, 143, 146).”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Wang, G.-J., Volkow, N. D., Logan, J., Pappas, N. R., Wong, C. T., Zhu, W., Netusll, N., & Fowler, J. S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03643-6 · Cited by 1,864
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Research works printed but not linked: 42
- 10.1016/s0140-6736(05)67483-1 · DOI · Paper page
- 10.2337/db08-0210 · DOI · Paper page
- 2000, WHO Consultation on Obesity
- 10.1016/S0140-6736(18)32822-8 · DOI · Paper page
- 10.1038/nrendo.2017.122 · DOI · Paper page
- 10.2165/00003495-199958040-00015 · DOI
- 10.1592/phco.20.4.270.34882 · DOI · Paper page
- Drew, 2007, Obesity management: update on orlistat, 817
- 10.2337/diacare.27.1.155 · DOI · Paper page
- 10.1136/bmj.39406.519132.ad · DOI
- 10.1016/s0014-2999(02)01422-x · DOI · Paper page
- 10.1001/jama.293.23.2873 · DOI · Paper page
- 10.2147/dddt.s55587 · DOI · Paper page
- 10.1038/nature14260 · DOI · Paper page
- Dutia, 2012, β-Endorphin antagonizes the effects of α-MSH on food intake and body weight, 4246
- 10.1007/s40265-015-0427-5 · DOI
- 10.1016/s0140-6736(10)60888-4 · DOI · Paper page
- Apovian, 2013, A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II), 935
- 10.1038/oby.2010.147 · DOI · Paper page
- 10.1007/978-3-642-24716-3_20 · DOI
- 10.1016/s0140-6736(11)60205-5 · DOI · Paper page
- 10.1038/oby.2011.330 · DOI · Paper page
- 10.1001/jama.2016.7602 · DOI · Paper page
- 10.1002/pds.3612 · DOI
- 10.1016/j.yend.2012.05.008 · doi:10.1016/j.yend.2012.05.008
- 10.1111/j.1467-789X.2011.00860.x · DOI
- 10.1038/nrendo.2011.77 · DOI · Paper page
- 10.1016/S0140-6736(17)30069-7 · DOI · Paper page
- 10.1016/S0140-6736(15)00803-X · DOI · Paper page
- 10.1016/j.rbmo.2017.03.023 · DOI · Paper page
- 10.1016/s2213-8587(19)30157-3 · DOI · Paper page
- 10.1056/nejmc1611289 · DOI · Paper page
- 10.2337/dc15-0772 · DOI · Paper page
- Wang, 2014, Effect of combined naltrexone and bupropion therapy on the brain’s reactivity to food cues, 682
- 10.4158/ep161356.esgl · DOI · Paper page
- 10.1038/clpt.2013.204 · DOI · Paper page
- 10.1007/s00018-014-1650-z · DOI
- 10.1038/s41591-018-0015-9 · DOI · Paper page
- Haws, 2020, Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome, 2133
- 10.1016/s0140-6736(08)61525-1 · DOI · Paper page
- 10.1038/ijo.2010.87 · DOI
- 10.1007/s00592-017-0994-x · DOI
Cited by
Locatelli, J. C., Costa, J. G., Haynes, A., Naylor, L. H., Fegan, P. G., Yeap, B. B., & Green, D. J. (2024) · Diabetes Care · doi:10.2337/dci23-0100 · Cited by 152
Obesity and Eating Disorders in Children and Adolescents: The Bidirectional Link
Stabouli, S., Erdine, S., Suurorg, L., Jankauskienė, A., & Lurbe, E. (2021) · Nutrients · doi:10.3390/nu13124321 · Cited by 123
Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH
Kang, G. G., Trevaskis, N. L., Murphy, A. J., & Febbraio, M. A. (2023) · iScience · doi:10.1016/j.isci.2022.105905 · Cited by 94
Pipek, L. Z., Moraes, W. A. F., Nobetani, R. M., Cortez, V. S., Condi, A. S., Taba, J. V., Nascimento, R. F. V., Suzuki, M. O., do Nascimento, F. S., de Mattos, V. C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57724-5 · Cited by 80
Jungnik, A., Arrubla Martinez, J., Plum‐Mörschel, L., Kapitza, C., Lamers, D., Thamer, C., Schölch, C., Desch, M., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14948 · Cited by 63
Metadata
- Authors
- Son, J. W., & Kim, S.
- Venue
- Diabetes & Metabolism Journal
- Publisher
- Korean Diabetes Association
- Published
- 2020-12-31
- Volume
- 44
- Issue
- 6
- Pages
- 802-818
- ISSN
- 2233-6079
- 2233-6087
- Cited by
- 134
- References
- 31
- Language
- en
- Licence
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive Review of Current and Upcoming Anti-Obesity Drugs. https://app.cochat.ai/papers/10.4093/dmj.2020.0258
- The paper
- Son, J. W., & Kim, S. (2020). Comprehensive Review of Current and Upcoming Anti-Obesity Drugs. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2020.0258
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.